Boehringer Ingelheim接受领导过渡,7月新任主席接任。 Boehringer Ingelheim undergoes leadership transition, with new chairs taking over in July.

一家大型生物制药公司Beeringer Ingelheim已宣布改变领导层。 Boehringer Ingelheim, a major biopharmaceutical firm, has announced changes in leadership. 克里斯蒂安·博赫林格将辞去股东委员会主席职务,由休伯特斯·冯·邦巴赫接替。 Christian Boehringer will step down as Chairman of the Shareholders' Committee, to be replaced by Hubertus von Baumbach. Von Baumbach随后将他担任总经理理事会主席的职位移交给Shashank Deshpande,后者还领导了人类制药商业股。 Von Baumbach will then hand over his position as Chairman of the Board of Managing Directors to Shashank Deshpande, who also leads the Human Pharma Business Unit. 更改于2025年7月1日生效。 The changes take effect on July 1, 2025.